In the present study, we designed a strategy to overcome barriers in solid tumor therapy by employing a combinatorial regimen consisting of DTIC followed by infusion of engineered EGFR mCAR T cells after lymphodepleting pre-conditioning with CPA, using a B16 melanoma model. The gene discussed is EGFR; the disease is melanoma.